Multichannel
Pharma needs a digital reset
Pharma knows the value of digital, yet it admits only a fraction of launches regularly succeed
More Articles
Patients and Medical
Digital patient engagement data: Are you already falling behind?
Gathering and acting on insights from digital patient engagement data is becoming a competitive differentiator, yet many in pharma are still stuck in learning mode
Commercial
The field force: Is small beautiful?
As big pharma ponders the right sizing of its post-pandemic field forces, can it learn from smaller, leaner industry peers about doing more with less?
Access and Evidence
How automation is changing regulatory affairs
Post pandemic, pharma and regulators are both working to accelerate the transformative power of electronic filing
Multichannel
Modularise to personalise
Digital-first engagement is challenging pharma to deliver content on HCPs’ terms and a modular approach is key
Commercial
Cell & Gene Therapy: High stakes and high hopes for healthcare
Now that CGT is proving its worth, the next task for pharma is working out the best ways to commercialise it
Clinical
Synthetic data: pharma’s next big thing?
Faster, better trials, enhanced pharmacoepidemiology and more ambitious cross-border research are just some of the likely use cases for synthetic data
Access and Evidence
An early peek at the FDA’s RWE ‘cookbook’
The FDA is developing guidelines that will help pharma accelerate its adoption of RWE, this is what the industry should know
Multichannel
The rise and rise of digital budgets
Spending on digital promotional and educational activity will continue to rise while promotional budgets for print decline
Medical
Taking clinical trials to the patient
Putting patients at the center of trials in Japan using new tools and approaches